Abstract

Actinomycetes are remarkable producers of compounds essential for human and veterinary medicine as well as for agriculture. The genomes of those microorganisms possess several sets of genes (biosynthetic gene cluster (BGC)) encoding pathways for the production of the valuable secondary metabolites. A significant proportion of the identified BGCs in actinomycetes encode pathways for the biosynthesis of polyketide compounds, nonribosomal peptides, or hybrid products resulting from the combination of both polyketide synthases (PKSs) and nonribosomal peptide synthetases (NRPSs). The potency of these molecules, in terms of bioactivity, was recognized in the 1940s, and started the “Golden Age” of antimicrobial drug discovery. Since then, several valuable polyketide drugs, such as erythromycin A, tylosin, monensin A, rifamycin, tetracyclines, amphotericin B, and many others were isolated from actinomycetes. This review covers the most relevant actinomycetes-derived polyketide drugs with antimicrobial activity, including anti-fungal agents. We provide an overview of the source of the compounds, structure of the molecules, the biosynthetic principle, bioactivity and mechanisms of action, and the current stage of development. This review emphasizes the importance of actinomycetes-derived antimicrobial polyketides and should serve as a “lexicon”, not only to scientists from the Natural Products field, but also to clinicians and others interested in this topic.

Highlights

  • More than 70 years has passed since the discovery of the first antibiotics from actinomycetes

  • Since polyketide-derived antimicrobials have had a historical significance in human therapy, this group of compounds remain important for continuation of research aiming at: the identification of new structures and activities, the biosynthesis and/or chemical semi-synthesis for discovery of novel derivatisation routes, and at understanding of resistance mechanisms to overcome this obstacle

  • This calls for the discovery and development of new antibiotics and antimicrobial strategies

Read more

Summary

Introduction

More than 70 years has passed since the discovery of the first antibiotics from actinomycetes. Are being put forward in order to limit the further spread of antimicrobial resistance [31] Some of these initiatives include the development of vaccines, faster diagnostic tests to ensure appropriate antibiotic administration, and immune-based therapies [32]. These measures could provide promising solutions for prevention of infections once infection occurs in a human host, antibiotics remain the choice of treatment for bacterial and fungal infections. Since polyketide-derived antimicrobials have had a historical significance in human therapy, this group of compounds remain important for continuation of research aiming at: the identification of new structures and activities, the biosynthesis and/or chemical semi-synthesis for discovery of novel derivatisation routes, and at understanding of resistance mechanisms to overcome this obstacle. This review should serve as a “lexicon” of actinomycetes-derived antimicrobial polyketides, to scientists from the Natural Products field, and to clinicians and others interested in this topic

The Biosynthetic Assembly Lines
Erythromycin and Derivatives
Tylosin
Monensins
Rifamycin and Derivatives
Tetracyclines
Streptogramins
Nystatin A1
Amphotericin B
Strategies and Tools for the Discovery of Natural Products
Findings
Conclusions and Outlook

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.